kras-pink-teal
TARGET KRAS WITH CONFIDENCE

KRASmut PDO SCREEN

Test the efficacy of your compound(s) in a panel of more than 25 patient-derived organoids representing colorectal, lung, and pancreatic cancer

lung-cancer

Colorectal
cancer

lung-cancer

Lung
cancer

pancreatic-cancer

Pancreatic
cancer

enroll now

Proven Impact

Our meticulously designed KRASmut panel was instrumental in developing the first-ever clinical candidate using organoid technology, targeting head & neck cancer

Panel features

  • Largest commercially available KRASmut PDO panel including more than 25 models
  • Representing pivotal KRAS mutants such as G12A, G12D, G12V, G13D and many others
  • Rigorously characterized, with readily available RNA or DNA sequencing data
  • Diverse models encompassing both primary and metastatic tumors
  • Test off-tumor toxicities with matched normal organoids
  • The most competitive pricing on the market when choosing a full panel screen

request access to panel

Advanced screening capabilities

  • Direct measurement of cell viability with an image-based viability readout
  • High-throughput 3D assay format 
  • Test as many compound(s) as you want
  • No minimum number of models to enroll 
  • High-data quality with 10-point dose-response curves per compound
  • Inclusive of IC50 determination and IC50 heatmap generation

enroll now

Screen Schedule 2024

Screen slot Registration deadline Study initiation
October
September 13th October 15th
November
October 15th November 14th
December November 14th December 5th

Test your compound on our adagrasib resistant PDO for free

Valid for any study of more than 4 PDOs 

Accelerate your KRAS drug development with our comprehensive portfolio

lead identification lead identification
Identify promising leads
Benchmarking with standard of care Benchmarking with standard of care
Benchmark against standard of care
Mode of action studies Mode of action studies
Understand the mechanism of action
Investigate the mechanism of resistance Investigate the mechanism of resistance
Investigate resistance mechanisms 
Combination treatment selection Combination treatment selection
Craft optimal combination
therapy
Co-clinical biomarker studies Co-clinical biomarker studies
Develop co-clinical
biomarker assays
Companion diagnostics Companion diagnostics
Companion
diagnostics partnering

book a consultation